Literature DB >> 35994136

Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease.

Ishaan Jindal1, Xiao Wang2.   

Abstract

PURPOSE OF REVIEW: To establish genome editing as a promising therapeutic approach for the treatment and prevention of atherosclerotic cardiovascular disease. RECENT
FINDINGS: Systemic delivery of a CRISPR adenine base editor using lipid nanoparticles demonstrated a near 90% reduction in circulating PCSK9 and over 60% reduction in blood LDL-C in nonhuman primates with the effects remaining durable at least 8 months following a single course. Preclinical proof-of-concept studies have elucidated the superior therapeutic potential of genome-editing approaches for the treatment of hyperlipidemia, thus substantiating their progression to clinical studies.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Atherosclerotic cardiovascular disease; CRISPR/Cas9; Genome editing; High cholesterol; Hyperlipidemia; One-and-done therapy

Mesh:

Substances:

Year:  2022        PMID: 35994136     DOI: 10.1007/s11883-022-01063-1

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.967


  11 in total

Review 1.  RNA interference.

Authors:  Gregory J Hannon
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

2.  Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases.

Authors:  Marina Bibikova; Mary Golic; Kent G Golic; Dana Carroll
Journal:  Genetics       Date:  2002-07       Impact factor: 4.562

Review 3.  CRISPR technologies for precise epigenome editing.

Authors:  Muneaki Nakamura; Yuchen Gao; Antonia A Dominguez; Lei S Qi
Journal:  Nat Cell Biol       Date:  2021-01-08       Impact factor: 28.824

Review 4.  PCSK9: a key modulator of cardiovascular health.

Authors:  Nabil G Seidah; Zuhier Awan; Michel Chrétien; Majambu Mbikay
Journal:  Circ Res       Date:  2014-03-14       Impact factor: 17.367

5.  Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage.

Authors:  Nicole M Gaudelli; Alexis C Komor; Holly A Rees; Michael S Packer; Ahmed H Badran; David I Bryson; David R Liu
Journal:  Nature       Date:  2017-10-25       Impact factor: 49.962

Review 6.  Moving toward genome-editing therapies for cardiovascular diseases.

Authors:  Kiran Musunuru
Journal:  J Clin Invest       Date:  2022-01-04       Impact factor: 14.808

7.  The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutations.

Authors:  Isabel De Castro-Orós; Miguel Pocoví; Fernando Civeira
Journal:  Appl Clin Genet       Date:  2010-08-05

8.  Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage.

Authors:  Alexis C Komor; Yongjoo B Kim; Michael S Packer; John A Zuris; David R Liu
Journal:  Nature       Date:  2016-04-20       Impact factor: 49.962

9.  Chemical modifications of adenine base editor mRNA and guide RNA expand its application scope.

Authors:  Tingting Jiang; Jordana M Henderson; Kevin Coote; Yi Cheng; Hillary C Valley; Xiao-Ou Zhang; Qin Wang; Luke H Rhym; Yueying Cao; Gregory A Newby; Hermann Bihler; Martin Mense; Zhiping Weng; Daniel G Anderson; Anton P McCaffrey; David R Liu; Wen Xue
Journal:  Nat Commun       Date:  2020-04-24       Impact factor: 14.919

10.  Search-and-replace genome editing without double-strand breaks or donor DNA.

Authors:  Andrew V Anzalone; Peyton B Randolph; Jessie R Davis; Alexander A Sousa; Luke W Koblan; Jonathan M Levy; Peter J Chen; Christopher Wilson; Gregory A Newby; Aditya Raguram; David R Liu
Journal:  Nature       Date:  2019-10-21       Impact factor: 69.504

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.